<p>Aardvark Therapeutics, Inc.是一家醫療保健行業公司，華爾街分析師於 5 月 15 日重新評估了該公司。來自美國銀行證券的分析師 Tazeen Ahmad 將該股票的評級下調至賣出，並給出了 4.00 美元的目標價。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Tazeen Ahmad 之所以給予賣出評級，是由於 FDA 對 Aardvark Therapeutics 的主要項目 ARD-101 的臨牀暫停所帶來的多種因素的綜合影響，以及由此產生的開發時間表的不確定性。由於在健康志願者中觀察到高劑量的心臟問題，該公司已暫停試驗，儘管管理層與 FDA 保持積極對話，並計劃在普拉德 - 威利綜合症的 3 期 HERO 和擴展數據中解除盲法，但尚未傳達明確的時間表。</p>
<p>Ahmad 還認為，由於監管環境的變化和來自 Soleno 的 Vykat XR 及 Rhythm 的 setmelanotide 等產品的競爭加劇，AARD 未來的市場機會面臨額外風險。反映這些擔憂，她降低了成功的概率，推遲了 PWS 項目的假定啓動，取消了之前分配給其他適應症和終端增長的價值，並提高了折現率，這些因素共同導致她將目標價從 18 美元下調至 4 美元，支持賣出立場。</p>
<p>在 5 月 15 日發佈的另一份報告中，摩根士丹利也將該股票評級下調至賣出，目標價為 3.00 美元。</p>

AARD

<p>Aardvark Therapeutics, Inc. 被美國銀行分析師 Tazeen Ahmad 下調至賣出評級，目標價從 18 美元下調至 4 美元。此次評級下調是由於 FDA 對其主要項目 ARD-101 因心臟問題實施臨牀暫停，以及來自其他產品的競爭加劇。摩根士丹利也將該股票下調至賣出，目標價為 3.00 美元</p>

<p>Aardvark Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on May 15. Analyst Tazeen Ahmad from Bank of America Securities downgraded the rating on the stock to a Sell and gave it a $4.00 price target.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc.是一家醫療保健行業公司，華爾街分析師於 5 月 15 日重新評估了該公司。來自美國銀行證券的分析師 Tazeen Ahmad 將該股票的評級下調至賣出，並給出了 4.00 美元的目標價。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Tazeen Ahmad has given his Sell rating due to a combination of factors centered on the FDA’s clinical hold of Aardvark Therapeutics’ lead program, ARD-101, and the resulting uncertainty around development timelines. The company has halted trials after cardiac issues were observed at higher doses in healthy volunteers, and although management is in active dialogue with the FDA and plans to unblind phase 3 HERO and extension data in Prader-Willi syndrome, no firm schedule has been communicated.</p>
<div class="lb-trans"><p>Tazeen Ahmad 之所以給予賣出評級，是由於 FDA 對 Aardvark Therapeutics 的主要項目 ARD-101 的臨牀暫停所帶來的多種因素的綜合影響，以及由此產生的開發時間表的不確定性。由於在健康志願者中觀察到高劑量的心臟問題，該公司已暫停試驗，儘管管理層與 FDA 保持積極對話，並計劃在普拉德 - 威利綜合症的 3 期 HERO 和擴展數據中解除盲法，但尚未傳達明確的時間表。</p>
</div><p>Ahmad also sees added risk from a changing regulatory environment and intensifying competition from products like Soleno’s Vykat XR and Rhythm’s setmelanotide, which could erode AARD’s future market opportunity. Reflecting these concerns, she lowers the probability of success and delays the assumed launch for the PWS program, removes value previously assigned to other indications and terminal growth, and raises discount rates, which collectively reduce her price objective from $18 to $4, supporting a Sell stance.</p>
<div class="lb-trans"><p>Ahmad 還認為，由於監管環境的變化和來自 Soleno 的 Vykat XR 及 Rhythm 的 setmelanotide 等產品的競爭加劇，AARD 未來的市場機會面臨額外風險。反映這些擔憂，她降低了成功的概率，推遲了 PWS 項目的假定啓動，取消了之前分配給其他適應症和終端增長的價值，並提高了折現率，這些因素共同導致她將目標價從 18 美元下調至 4 美元，支持賣出立場。</p>
</div><p>In another report released on May 15, Morgan Stanley also downgraded the stock to a Sell with a $3.00 price target.</p>
<div class="lb-trans"><p>在 5 月 15 日發佈的另一份報告中，摩根士丹利也將該股票評級下調至賣出，目標價為 3.00 美元。</p>
</div>

FDA Clinical Hold, Competitive Pressure Drive Aardvark Therapeutics Downgrade as Price Target Slashed from $18 to $4

Tip Ranks

Aardvark Therapeutics

美國銀行

Soleno治療

Rhythm Pharma

摩根士丹利

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

由於 FDA 臨牀暫停和競爭壓力，Aardvark Therapeutics 的評級被下調，目標價格從 18 美元大幅削減至 4 美元